Rejoinder to “A hybrid phase I‐II/III clinical trial design allowing dose reoptimization in phase III”

Andrew G. Chapple and Peter F. Thall

Biometrics, 2019, vol. 75, issue 2, 389-391

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/biom.12991

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:75:y:2019:i:2:p:389-391

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X

Access Statistics for this article

More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().